Anti-PD-1 antibody therapy for recurrent / progressive Meningioma: an investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial.

Sasaki Hikaru0 sites29 target enrollmentStarted: August 20, 2019Last updated: November 20, 2023

Conditions

Trial Snapshot

Phase: Phase 2
Status: Completed
Sponsor
Enrollment: 29

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional

Eligibility Criteria

Ages: >= 20age old to <= 79age old (—)
Sex: All

Inclusion Criteria

•1) Older than or equal to 20 years old, younger than 80 years old
•2) Diagnosis of meningioma (WHO Grade I - III)
•3) History of tumor resection and radiation therapy for meningioma
•4) Evidence of recurrence or progression of meningioma after the last treatment for meningioma, and patients who meet either of the following conditions
•(1) Neither tumor resection nor radiation therapy is deemed effective for the recurrent/progressive meningioma
•(2) Patient who does not wish to have further treatment by tumor resection or radiation therapy
•5) Patient who have passed a certain period of time since the last treatment.: 4 weeks after tumor resection. 1 week after biopsy. 12 weeks after radiation therapy/chemotherapy/medication therapy/immunotherapy. It is not necessary to pass 12 weeks, in the case of recurrence or progression out of the radiation field.
•6) Patient with a lesion difined as measurable lesion in RANO(meningioma) with diagnostic imaging taken within 14 days before registration.
•7) Patient who is possible to submit tumor tissue sample which was daignosed with menigioma.
•8) Karnofsky Performance Status more than or equal to 70%.
•9) Patients expected to survive 12 weeks or more at the time when the consent is obtained.
•10) Patient with adequate laboratory data.

Exclusion Criteria

•1) Cooccurence of cancer other than meningioma. However, completely resected basal cell carcinoma, Stage I squamous cell carcinoma, carcinoma in situ, superficial bladder carcinoma, or any other cancer without recurrence for more than 3 years are allowed.
•2) Comorbid autoimmune diseases or history of chronic or recurrent autoimmune diseases.
•3) Patient with intracranial hemorrhage with diagnositc imaging taken within 14 days before registration.
•4) Patient with uncontrollable hypertension despite appropriate treatment.
•5) Central nervous system diseases other than meningioma (eg, epilepsy, etc.) that are not well controlled or may lead to discontinuation of the investigational drug.
•6) Patient has or previously had a history of pulmonary hemorrhage/hypoemia.
•7) Patient has or previously had a history of hereditary hemorrhagic predisposition or serious coagulation disorders at risk of hemorrhage.
•8) Patient undergoing anticoagulation therapy excluding for preventive medication.
•9) Patient with active gastrointestinal ulcer or gastrointestinal bleeding.
•10) Patient with a history of cerebral infarction or arteriovenous thromboembolism within 180 days before registration.
•11) Patient with uncontrollable or serious cardiovascular disease.
•12) Patient with uncontrollable diabetes mellitus.
•13) Patient with infections requiring systemic treatment.
•14) Patient with pulmonary fibrosis or interstitial pneumonia.
•15) Patient being treated with immunosuppressants.
•16) Patient being treated with corticosteroids. Use of 2.0 mg / day or less of dexamethasone or 10 mg / day or less of prednisolone is acceptable. Short-term use of corticosteroids for the prevention of anaphylaxis, topical (skin, airway etc) corticosteroids use is acceptable.
•17) Patient who can not or do not wish to have MRI imaging or contrast-enhanced MRI imaging due to pacemaker, implantable defibrillator use or contrast agent allergy.
•18) Patient with a history of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody or other antibody or drug therapy aimed at T cell control.
•19) Patient judged to lack consent ability. (e.g. dementia)

Investigators

Sponsor

Sasaki Hikaru

Similar Trials

Active, not recruiting

Phase 1

Administration of an anti-cancer therapy, which is based on release of brakes in the natural immune response, in patients which are planned to subsequently undergo surgery for removal of their non-small cell lung cancernon-small cell lung cancer (NSCLC), resectableMedDRA version: 20.1 Level: PT Classification code 10029520 Term: Non-small cell lung cancer stage IIIA System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029518 Term: Non-small cell lung cancer stage II System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-000105-20-DEAIO-Studien-gGmbH30

Recruiting

Not Applicable

Prospective study of anti-PD-1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-L1 antibodylung cancer

JPRN-UMIN000033657Japanese Red Cross Medical Center30

Recruiting

Not Applicable

Prospective study of anti-PD-L1 antibody therapy in advanced non-small cell lung cancer patients who previously treated with anti-PD-1 antibodylung cancer

JPRN-UMIN000033288Japanese Red Cross Medical Center30

Active, not recruiting

Phase 1

Immunotherapeutic treatment with Pembrolizumab (antibody) in melanoma patients at high risk of recurrence after complete surgical resectioStage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mmany Stage IIIB or IIIC (no in-transit metastases)MedDRA version: 21.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2014-004944-37-PLMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900

Active, not recruiting

Phase 1

EUCTR2014-004944-37-FIMerck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc900